Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
NASDAQ-listed (WBA) US pharmacy giant with 8,700 stores going private via Sycamore Partners LBO in 2024; major restructuring after 70% stock decline, clinic write-downs, and dividend cuts.
Walgreens Boots Alliance (NASDAQ: WBA) is the largest US pharmacy chain and global pharmacy-led health and wellness company — operating approximately 8,700 Walgreens locations in the US alongside Boots pharmacies in the UK and other international markets, providing prescription medications, over-the-counter health products, beauty items, and health clinic services through the largest drugstore footprint in the US. WBA generated $147 billion in revenue in fiscal year 2024 and serves approximately 9 million customers daily, making it one of the most visited retail destinations in the US.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.